Announcement on the postponement of some fund-raising investment projects
Legal opinion of Peking Jingtian & Gongcheng Law Firm on the 2023 annual shareholders meeting of CansinoBio Technology Co., Ltd.
Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023
Materials for the 2023 Annual Shareholders Meeting.
Announcement on the Resignation of Non-Executive Directors and Election of Non-Executive Directors and Members of the Special Committee on the Adjustment of the Board
Notice on convening the 2023 Annual General Meeting of Shareholders
Notice of Response to the Information Disclosure Regulatory Inquiry Letter on the 2023 Annual Report
Voluntary Disclosure Notice on Positive Preliminary Phase I Clinical Results of the Recombinant Pneumococcal Protein Vaccine
Announcement on preparation for impairment of assets accrued in 2023
Announcement on the re-signing of the “Concerted Action Agreement” by the controlling shareholder and actual controller
2023 Internal Control Evaluation Report
2023 Annual Report of the Board of Directors Audit Committee
Special report of the board of directors on the self-inspection of the independence of independent directors
Report of the Audit Committee on the performance of supervisory duties by accounting firms in 2023
2024 “Improve Quality, Increase Efficiency, and Focus on Return” Action Plan
Notice on Using Idle Own Funds for Cash Management
Notice on requesting the shareholders' meeting to authorize the board of directors to issue shares to specific targets through simple procedures
Voluntary disclosure announcement on initiation of phase III clinical trial of adsorbed tetanus vaccine and completion of enrollment of the first patient
Notice on matters involving the company in litigation
Voluntary Disclosure Notice Regarding Acceptance of Drug Registration Applications for 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT Carrier)
No Data